
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group is a promising company with strong potential in the medical technology industry. The company's Organ Care System (OCS) technology has the potential to transform the organ transplantation process by replicating near-physiologic conditions for donor organs. However, there are several risks that could impact the company's future prospects, including limited market commercialization experience, regulatory challenges, and customer concentration. Despite these risks, the company's solid financial performance and potential for further growth make it an attractive investment opportunity.
Bears say
TransMedics Group is facing increased expenses and projected decrease in earnings per share, with potential external factors such as OPO modernization and competition from XVIVO's HOPE technology. Surgeons have mixed opinions on TMDX becoming an OPO, but the company remains a growth company with potential for success. Decreasing costs in the market may also impact the company's competitiveness and surgeons may consider cheaper alternatives for organ preservation methods. While the company has acquired new R&D, it is important to closely monitor its financials and market developments.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares